348 related articles for article (PubMed ID: 24187130)
1. Development of functionally selective, small molecule agonists at kappa opioid receptors.
Zhou L; Lovell KM; Frankowski KJ; Slauson SR; Phillips AM; Streicher JM; Stahl E; Schmid CL; Hodder P; Madoux F; Cameron MD; Prisinzano TE; Aubé J; Bohn LM
J Biol Chem; 2013 Dec; 288(51):36703-16. PubMed ID: 24187130
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias.
Lovell KM; Frankowski KJ; Stahl EL; Slauson SR; Yoo E; Prisinzano TE; Aubé J; Bohn LM
ACS Chem Neurosci; 2015 Aug; 6(8):1411-9. PubMed ID: 25891774
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel functionally selective κ-opioid receptor scaffolds.
White KL; Scopton AP; Rives ML; Bikbulatov RV; Polepally PR; Brown PJ; Kenakin T; Javitch JA; Zjawiony JK; Roth BL
Mol Pharmacol; 2014 Jan; 85(1):83-90. PubMed ID: 24113749
[TBL] [Abstract][Full Text] [Related]
4. The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.
White KL; Robinson JE; Zhu H; DiBerto JF; Polepally PR; Zjawiony JK; Nichols DE; Malanga CJ; Roth BL
J Pharmacol Exp Ther; 2015 Jan; 352(1):98-109. PubMed ID: 25320048
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
[TBL] [Abstract][Full Text] [Related]
6. Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses.
Dunn AD; Reed B; Erazo J; Ben-Ezra A; Kreek MJ
ACS Chem Neurosci; 2019 Aug; 10(8):3590-3600. PubMed ID: 31313902
[TBL] [Abstract][Full Text] [Related]
7. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
8. Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.
Schmid CL; Streicher JM; Groer CE; Munro TA; Zhou L; Bohn LM
J Biol Chem; 2013 Aug; 288(31):22387-98. PubMed ID: 23775075
[TBL] [Abstract][Full Text] [Related]
9. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.
Brust TF; Morgenweck J; Kim SA; Rose JH; Locke JL; Schmid CL; Zhou L; Stahl EL; Cameron MD; Scarry SM; Aubé J; Jones SR; Martin TJ; Bohn LM
Sci Signal; 2016 Nov; 9(456):ra117. PubMed ID: 27899527
[TBL] [Abstract][Full Text] [Related]
10. Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology.
Brust TF
Handb Exp Pharmacol; 2022; 271():115-135. PubMed ID: 33140224
[TBL] [Abstract][Full Text] [Related]
11. The orexin 1 receptor modulates kappa opioid receptor function via a JNK-dependent mechanism.
Robinson JD; McDonald PH
Cell Signal; 2015 Jul; 27(7):1449-56. PubMed ID: 25857454
[TBL] [Abstract][Full Text] [Related]
12. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse.
Khan MIH; Sawyer BJ; Akins NS; Le HV
Eur J Med Chem; 2022 Dec; 243():114785. PubMed ID: 36179400
[TBL] [Abstract][Full Text] [Related]
13. Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
[TBL] [Abstract][Full Text] [Related]
14. Kinase cascades and ligand-directed signaling at the kappa opioid receptor.
Bruchas MR; Chavkin C
Psychopharmacology (Berl); 2010 Jun; 210(2):137-47. PubMed ID: 20401607
[TBL] [Abstract][Full Text] [Related]
15. 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.
Rives ML; Rossillo M; Liu-Chen LY; Javitch JA
J Biol Chem; 2012 Aug; 287(32):27050-4. PubMed ID: 22736766
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.
Abraham AD; Schattauer SS; Reichard KL; Cohen JH; Fontaine HM; Song AJ; Johnson SD; Land BB; Chavkin C
J Neurosci; 2018 Sep; 38(37):8031-8043. PubMed ID: 30076211
[TBL] [Abstract][Full Text] [Related]
17. G protein signaling-biased agonism at the κ-opioid receptor is maintained in striatal neurons.
Ho JH; Stahl EL; Schmid CL; Scarry SM; Aubé J; Bohn LM
Sci Signal; 2018 Aug; 11(542):. PubMed ID: 30087177
[TBL] [Abstract][Full Text] [Related]
18. Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.
Gross JD; Kaski SW; Schmidt KT; Cogan ES; Boyt KM; Wix K; Schroer AB; McElligott ZA; Siderovski DP; Setola V
Neuropsychopharmacology; 2019 Sep; 44(10):1728-1741. PubMed ID: 31141817
[TBL] [Abstract][Full Text] [Related]
19. Biosensors Monitor Ligand-Selective Effects at Kappa Opioid Receptors.
Oberhauser L; Stoeber M
Handb Exp Pharmacol; 2022; 271():65-82. PubMed ID: 33387066
[TBL] [Abstract][Full Text] [Related]
20. Oxytocin Is a Positive Allosteric Modulator of κ-Opioid Receptors but Not δ-Opioid Receptors in the G Protein Signaling Pathway.
Miyano K; Yoshida Y; Hirayama S; Takahashi H; Ono H; Meguro Y; Manabe S; Komatsu A; Nonaka M; Mizuguchi T; Fujii H; Higami Y; Narita M; Uezono Y
Cells; 2021 Oct; 10(10):. PubMed ID: 34685631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
